** Citi cuts PT on Australian ultrasound probe disinfector
manufacturer Nanosonics Inc NAN.AX to A$3.65 from A$4.00;
maintains "sell" rating
** Forecasts operational expenditure (opex) of A$91 mln in
FY22 and A$110 mln in FY23, up significantly on continued
investments
** Citi says NAN's Q3 trading update mentions management's
expectation that majority of GE customers would have
transitioned to NAN by June end as NAN transitions to a direct
sales model in the U.S.
** Citi flags that one-off FY22 revenue impact from the
direct sales model is expected to be in the range of A$13 mln -
A$16 mln ($9.34 million - $11.49 million)
** Four of 10 analysts rate the stock "buy" or higher, two
"hold" and four "sell" or lower; their median PT is A$4.78 –
Refinitiv data
** Stock has fallen 41.4% this year
($1 = 1.3922 Australian dollars)
(Reporting by Jaskiran Singh in Bengaluru)
((Jaskiran.Singh@thomsonreuters.com;))